Versant Capital Management’s Harmony Biosciences HRMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$14.3K Hold
364
– – ﹤0.01% 2123
2026
Q2
$13.3K Buy
364
+343
+1,633% +$10.8K ﹤0.01% 2133
2026
Q1
$588 Buy
21
+6
+40% +$197 ﹤0.01% 2710
2025
Q4
$561 Sell
15
-336
-96% -$11K ﹤0.01% 2578
2025
Q3
$9.7K Buy
351
+100
+40% +$3.44K ﹤0.01% 1953
2025
Q2
$7.93K Buy
251
+96
+62% +$3.09K ﹤0.01% 1989
2025
Q1
$5.14K Hold
155
– – ﹤0.01% 2018
2024
Q4
$5.33K Buy
155
+140
+933% +$4.81K ﹤0.01% 1724
2024
Q3
$600 Hold
15
– – ﹤0.01% 1840
2024
Q2
$453 Hold
15
– – ﹤0.01% 1806
2024
Q1
$504 Hold
15
– – ﹤0.01% 1689
2023
Q4
$485 Sell
15
-7
-32% -$195 ﹤0.01% 1688
2023
Q3
$721 Hold
22
– – ﹤0.01% 1622
2023
Q2
$774 Hold
22
– – ﹤0.01% 1690
2023
Q1
$719 Sell
22
-44
-67% -$2K ﹤0.01% 1525
2022
Q4
$3.64K Hold
66
– – ﹤0.01% 986
2022
Q3
$3K Buy
66
+44
+200% +$2.15K ﹤0.01% 983
2022
Q2
$1K Buy
+22
New +$990 ﹤0.01% 1267

Other funds holding HRMY

Versant Capital Management's HRMY Position: Q3 2026 in Review

Versant Capital Management held its Harmony Biosciences (HRMY) position steady in Q3 2026 at 364 shares worth $14.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2123.

Versant Capital Management first reported a position in HRMY in Q2 2022 and has held it in 18 quarters since. 358 funds tracked by Wall St. Rank hold HRMY as of Q3 2026.

  • Versant Capital Management held 364 shares of Harmony Biosciences worth $14.3K as of Q3 2026.
  • Versant Capital Management left its Harmony Biosciences share count unchanged in Q3 2026.
  • Harmony Biosciences made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2123 holding.
  • Versant Capital Management first reported a position in Harmony Biosciences in Q2 2022 and has held it in 18 quarters since.
  • 358 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.